| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2013;3(5):397-407
Original Article
A comparison of PET imaging agents for the assessment of therapy efficacy in a
rodent model of glioma
Shehzahdi S Moonshi, Romain Bejot, Zeenat Atcha, Vimalan Vijayaragavan, Kishore K Bhakoo, Julian L Goggi
Singapore Bioimaging Consortium (A*STAR), Helios, 02-02, 11 Biopolis Way, 138667 Singapore; Department of Physiology, Yong
Loo Lin School of Medicine, National University of Singapore, 117456 Singapore
Received June 19, 2013; Accepted July 9, 2013; Epub September 19, 2013; Published September 30, 2013
Abstract: The aim of the current study was to assess the ability of PET imaging agents to detect early response to therapy in an
orthotopic experimental rodent model of glioma. Clinically, MRI and [18F]FDG PET are routinely used but their ability to assess early
therapeutic response can be limited. In this study, nude rats were implanted with U87-MG tumors orthotopically and imaged with
either [18F]FDG or [18F]FLT to determine which tracer acts as the most sensitive biomarker for evaluation of treatment response in
animals undergoing anti-angiogenic therapy with sunitinib, a receptor tyrosine kinase (RTK) inhibitor. Of the radiopharmaceuticals
tested, [18F]FLT proved to be the most sensitive biomarker in the proliferating glioma, based on tumour-to-normal tissue radiotracer
uptake (TNR ~17) in comparison to [18F]FDG (TNR ~1.7). Furthermore, [18F]FLT displayed earlier assessment of therapy efficacy,
than either tumour volume measured by MRI or [18F]FDG PET imaging. Overall, longitudinal molecular imaging with [18F]FLT
provides earlier detection of therapy response than either of the commonly used clinical imaging modalities potentially improving
patient management. (ajnmmi1306002).
Keywords: PET, glioma, sunitinib, [18F]FLT, [18F]FDG, angiogenesis, orthotopic
Address correspondence to: Dr. Julian L Goggi, Singapore Bioimaging Consortium (A*STAR), Helios, 02-02, 11 Biopolis Way,
138667 Singapore. Tel: (+65) 6478 8901; Fax: (+65) 6478 8908; E-mail: julian_goggi@sbic.a-star.edu.sg
Original Article
A comparison of PET imaging agents for the assessment of therapy efficacy in a
rodent model of glioma
Shehzahdi S Moonshi, Romain Bejot, Zeenat Atcha, Vimalan Vijayaragavan, Kishore K Bhakoo, Julian L Goggi
Singapore Bioimaging Consortium (A*STAR), Helios, 02-02, 11 Biopolis Way, 138667 Singapore; Department of Physiology, Yong
Loo Lin School of Medicine, National University of Singapore, 117456 Singapore
Received June 19, 2013; Accepted July 9, 2013; Epub September 19, 2013; Published September 30, 2013
Abstract: The aim of the current study was to assess the ability of PET imaging agents to detect early response to therapy in an
orthotopic experimental rodent model of glioma. Clinically, MRI and [18F]FDG PET are routinely used but their ability to assess early
therapeutic response can be limited. In this study, nude rats were implanted with U87-MG tumors orthotopically and imaged with
either [18F]FDG or [18F]FLT to determine which tracer acts as the most sensitive biomarker for evaluation of treatment response in
animals undergoing anti-angiogenic therapy with sunitinib, a receptor tyrosine kinase (RTK) inhibitor. Of the radiopharmaceuticals
tested, [18F]FLT proved to be the most sensitive biomarker in the proliferating glioma, based on tumour-to-normal tissue radiotracer
uptake (TNR ~17) in comparison to [18F]FDG (TNR ~1.7). Furthermore, [18F]FLT displayed earlier assessment of therapy efficacy,
than either tumour volume measured by MRI or [18F]FDG PET imaging. Overall, longitudinal molecular imaging with [18F]FLT
provides earlier detection of therapy response than either of the commonly used clinical imaging modalities potentially improving
patient management. (ajnmmi1306002).
Keywords: PET, glioma, sunitinib, [18F]FLT, [18F]FDG, angiogenesis, orthotopic
Address correspondence to: Dr. Julian L Goggi, Singapore Bioimaging Consortium (A*STAR), Helios, 02-02, 11 Biopolis Way,
138667 Singapore. Tel: (+65) 6478 8901; Fax: (+65) 6478 8908; E-mail: julian_goggi@sbic.a-star.edu.sg
 |  |  |  |  |  |  |